Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, specializing in innovative therapies for liver diseases, including non-alcoholic steatohepatitis (NASH) and other related conditions. With a robust pipeline, the company leverages its proprietary drug platform to address significant unmet medical needs in hepatology. Galmed's lead candidate, Aramchol, has shown promising results in clinical trials, positioning the company strategically for future growth and potential partnerships within the rapidly evolving biopharmaceutical landscape.